Recommendations regarding indications for treatment in CLL
| . | General practice . | Clinical trial . |
|---|---|---|
| Treat with Rai stage 0 | NGI* | RQ |
| Treat with Binet stage A | NGI* | RQ |
| Treat with Binet stage B or Rai stage I or Rai stage II | Possible* | Possible* |
| Treat with Binet stage C or Rai stage III or Rai stage IV | Yes | Yes |
| Treatment of active/progressive disease | Yes | Yes |
| Treat without active/progressive disease | NGI | RQ |
| . | General practice . | Clinical trial . |
|---|---|---|
| Treat with Rai stage 0 | NGI* | RQ |
| Treat with Binet stage A | NGI* | RQ |
| Treat with Binet stage B or Rai stage I or Rai stage II | Possible* | Possible* |
| Treat with Binet stage C or Rai stage III or Rai stage IV | Yes | Yes |
| Treatment of active/progressive disease | Yes | Yes |
| Treat without active/progressive disease | NGI | RQ |
General practice is defined as the use of accepted treatment options for a patient with CLL who is not enrolled in a clinical trial.
NGI indicates not generally indicated; and RQ, research question.
Treatment is indicated if the disease is active as defined in section 4.